Impulse Dynamics®, a Marlton-based leader in medical device innovation based in Burlington County, announced today the appointment of Richard Buchholz as its new chief financial officer, effective March 2. The move signals a major strategic pivot for the Marlton-headquartered company as it prepares to scale its life-saving heart failure technologies following a massive $158 million funding round.
Buchholz is a heavy hitter in the medical technology sector, most recently serving as CFO for Inspire Medical Systems. During his decade-long tenure there, he grew the company from a $3.8 million operation into a $910 million powerhouse, overseeing a successful IPO and raising over $500 million in capital.
The appointment comes at a transformative time for Impulse Dynamics and the South Jersey medical technology corridor. In late 2025, the company closed a $158 million Series F financing round, one of the largest in the region, to accelerate the commercialization of its proprietary Cardiac Contractility Modulation (CCM®) therapy.
“Rick is an accomplished executive with a proven track record,” said Jason Spees, CEO of Impulse Dynamics. “I am thrilled to welcome him at a time when we are poised for our next phase of growth.”
Impulse Dynamics is currently making waves in the clinical community with its Optimizer® system. Unlike traditional pacemakers or defibrillators, the Optimizer delivers CCM therapy—precisely timed electrical pulses that help the heart contract more effectively without increasing its oxygen consumption.
Key recent milestones:
-
CMS Coverage: In October 2025, the Centers for Medicare and Medicaid Services issued a National Coverage Determination (NCD) for CCM therapy, removing a primary financial barrier for over 66 million patients.
-
INTEGRA-D Trial: The company is currently testing the CCM-D® HF System, a “two-in-one” device that treats heart failure symptoms while providing the protection of an implantable cardioverter defibrillator (ICD).
-
AIM HIGHer Study: This trial focuses on diastolic heart failure, a condition with historically few treatment options.
With Buchholz at the financial helm, Impulse Dynamics is widely expected to transition from a high-growth private firm toward a potential public offering, mirroring his previous success at Inspire. This growth contributes to New Jersey’s standing as a global hub for cardiovascular innovation, joining the ranks of major pharmaceutical and biotech firms anchored in the state.
“It is an honor to join this exciting and innovative company,” Buchholz said. “I look forward to working on a financial strategy that will continue the acceleration for a proprietary technology enabling a large population of heart failure patients to find a better quality of life.”
